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Abstract
Background: Dried blood spots (DBS) have been used as alternative specimens to plasma to increase access to HIV viral
load (VL) monitoring and early infant diagnosis (EID) in remote settings. We systematically reviewed evidence on the
performance of DBS compared to plasma for VL monitoring and EID.
Methods and Findings: Thirteen peer reviewed HIV VL publications and five HIV EID papers were included. Depending on
the technology and the viral load distribution in the study population, the percentage of DBS samples that are within 0.5
log of VL in plasma ranged from 52–100%. Because the input sample volume is much smaller in a blood spot, there is a risk
of false negatives with DBS. Sensitivity of DBS VL was found to be 78–100% compared to plasma at VL below 1000 copies/
ml, but this increased to 100% at a threshold of 5000 copies/ml. Unlike a plasma VL test which measures only cell free HIV
RNA, a DBS VL also measures proviral DNA as well as cell-associated RNA, potentially leading to false positive results when
using DBS. The systematic review showed that specificity was close to 100% at DBS VL above 5000 copies/ml, and this
threshold would be the most reliable for predicting true virologic failure using DBS. For early infant diagnosis, DBS has a
sensitivity of 100% compared to fresh whole blood or plasma in all studies.
Conclusions: Although limited data are available for EID, DBS offer a highly sensitive and specific sampling strategy to make
viral load monitoring and early infant diagnosis more accessible in remote settings. A standardized approach for sampling,
storing, and processing DBS samples would be essential to allow successful implementation.
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Introduction
According to the latest WHO figures, 34 million people were
living with HIV worldwide in 2011 [1]. As of mid-2012, over eight
million HIV infected individuals have been placed on antiretro-
viral therapy (ART) and will require ongoing monitoring to ensure
treatment continues to be efficacious [2]. While CD4 cell count
has traditionally been used to monitor patients on treatment in
resource-limited settings, HIV viral load (VL) testing is increas-
ingly recognized as the preferred tool for monitoring treatment
efficacy, detecting treatment failure, and preventing misclassifica-
tion of treatment responses and inappropriate switching of
treatment regimens [3]. However, despite recommendations by
WHO in 2010 for countries to begin phasing in VL monitoring,
current VL technology remains out of reach for the majority of
patients in most resource-limited settings as standard HIV nucleic
acid approaches depend on expensive equipment, dedicated
laboratory space and highly trained laboratory technologists [4,5].
Similarly, access to HIV nucleic acid detection for confirmation
of early infant diagnosis of HIV infection is a challenge. Antibody
detection assays cannot be used for infants less than 18 months of
age as maternal IgG antibodies can cross the placental barrier and
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yield false positive results. Assays to detect HIV nucleic acids are
more technically demanding and costly than simple antibody tests
and are neither affordable nor widely available [4,5]. Among
these, the most promising is the use of dried blood spots (DBS).
The process of DBS collection begins with a finger or heel prick
and spotting whole blood directly onto filter paper, which is then
left to dry at room temperature. Once dried, DBS can be stored
with desiccant and shipped to central laboratories for HIV
virologic testing. DBS has several advantages over traditional
methods of sample collection: there is no need for phlebotomy;
DBS increases the accessibility of HIV VL and EID testing in
remote areas; it is a relatively easy and inexpensive means of
collecting and storing samples under field conditions; DBS is easy
to transport from peripheral site to central laboratory; and DBS
reduces materials required, biological waste produced and
sampling costs for specimen collection compared to venipuncture
Figure 1. Search algorithm.
doi:10.1371/journal.pone.0086461.g001
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[6–10]. The use of DBS as an alternative sampling method for
HIV VL and EID assays may influence sensitivity and accuracy
[11].
Methods
We performed a systematic review of studies evaluating and
comparing the performance of DBS samples to plasma for HIV
VL quantification, and DBS for EID to whole blood (Appendix
S1).
Eligibility criteria
Eligibility criteria were defined using the PICOS format
(Population, Interventions, Comparisons, Outcomes, Study De-
sign). Studies evaluating DBS and plasma samples for HIV VL
measures with commercially available technologies at the time of
the review (April 2012) were considered for inclusion.
Search strategy
Studies published between January 1998 and April 2012 were
identified by a search of MEDLINE and Embase databases. A
separate search strategy was used for HIV VL search and EID as
defined in the study protocol (Appendix S1). Further studies were
identified by members of the WHO HIV Monitoring Technol-
ogies working group and considered for inclusion in the review.
Study selection
Titles and abstracts were screened for relevance and eligible
articles subjected to a full review of the text and assessed against
inclusion criteria. The inclusion criteria were: evaluation or
comparison of performance of commercially available VL
quantification assays or EID assays; evaluation of DBS with valid
reference sample using the same VL or EID technology; any HIV-
1 subgroup recognition.
Data extraction
Data were extracted from included studies into an excel file
which comprised of general information, study characteristics,
participant or sample characteristics, reference and index tech-
nology, and outcome data or results including data on accuracy
(bias, sensitivity and specificity) and precision (co-efficient of
variation). Two independent reviewers extracted data and where
discrepancies occurred, agreement was reached through discussion
and further article review.
Quality assessment
Each of the thirteen HIV VL articles and five EID articles
included in the review were assessed for quality by two
independent reviewers. Twenty four criteria, based on the
STARD guidelines, were used to assess the quality of publications
[12,13]. Each reviewer independently scored the publications on
the twenty-four quality criteria with a binary yes/no response. In
the case of a disagreement, the reviewers discussed the discrepancy
until a consensus could be reached.
Results
Characteristics of included studies
For HIV VL, 473 articles were retrieved and 13 articles were
included in the final review. For EID, 225 articles were retrieved
and 5 articles were included in the final review (Figure 1).
Thirteen studies evaluated the performance of quantitative HIV
VL assays, comparing DBS to plasma samples [11,14–25]. All
studies used Whatman filter paper 903 (protein saver card, GE
healthcare, USA). DBS was compared to plasma samples on
Abbott RealTime HIV-1 assay, M2000 platform (n= 6); four
studies used Biomerieux NucliSens easyQ v1.1 (n = 1), and v1.2
(n = 3), Roche COBAS Taqman HIV-1 VL (n= 1), Roche
Amplicor Monitor v1.5 (n = 2), and the Versant HIV-1 kPCR
(n= 1)(Appendix S2). DBS VL results were compared to plasma
results on the same platform. One study conducted plasma and
DBS samples in one run, while all remaining evaluations used two
runs to quantitate HIV VL using DBS and plasma samples [16].
The sensitivity and specificity of DBS samples on VL assays are
summarized in Table 1.
Five studies evaluated the performance of EID assays,
comparing the performance of DBS samples to the reference
sample of whole blood or plasma [26–29]. Four studies used
Whatman 903 filter paper [18,26,28,29] and one study used
Whatman No. 1 filter paper [27]. One study evaluated the
performance of a HIV VL assay for EID; these results are
presented below [19]. Three studies used Amplicor 1.5 assay, 1
used Cobas Taqman and evaluated the Amplicor 1.5 assay, and
one used NucliSens EasyQ (Appendix S2). Although Amplicor
v1.5 will eventually be phased out by Roche, its performance is still
important as it has been the gold standard for the past 20 years
and will be the reference assay against which new assays are
compared. The samples used for the evaluations were taken from
infants younger than 18 months [26,27], 6 weeks old [28], 8 weeks
old [18], and children between 6 weeks and 6 years [29]. The
Table 1. Sensitivity and Specificity of DBS for HIV VL compared to plasma.
Author Assay VL Threshold (copies/mL) Sample size Sensitivity (%)* Specificity (%)*
Lofgren et al. [19] RealTime 1000 176** 100 99
RealTime 10000 176** 100 100
RealTime 400 137` 99 87
RealTime 5000 137` 100 97
Pirillo et al. [22] kPCR 37 98 88.2 69.2
kPCR 5000 98 85.1 96.1
Rottinghaus et al. [23] NucliSens v.1.1 1000 173 77.8 98.1
*sensitivity and specificity given against plasma.
** infants (median 6 months, none on ART).
`adults (median 34 years, all on ART).
doi:10.1371/journal.pone.0086461.t001
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sensitivity and specificity of DBS samples on EID assays are given
in Table 2.
Sample preparation
DBS samples were prepared with either blood collected with
EDTA from a venipuncture [11,14–17,19–23,25,27–29] or heel
prick blood [18,26,28]. Sample storage conditions for DBS varied
from 37uC [17], 24uC [11], 220uC [14,15], 270uC [18,27] to
ambient temperatures [16,19–22,24,25,28,29], or any combina-
tion of temperatures [23]. Samples in VL studies were humidity
controlled with desiccants [14,15,19,22–25] but five studies did
not specify if desiccants were used [11,16,17,20,21]. Plasma
samples were stored at 270 or 280uC [14,19,22,23,25], 220uC
[11,15,16] or not specified [24,25]. Samples in all EID studies
were humidity controlled with desiccants [14,15,18,19,22–29].
Blood samples were stored at 270 or 280uC [18,27,29], or not
specified [26,28]. All VL studies included samples with a plasma
HIV VL range starting from 2 or 3 log10 copies up to 7 log10
copies/mL (Appendix S2).
The HIV VLs obtained by DBS samples, which contain
approximately 50–100 ml of whole blood, were compared to
plasma samples in thirteen studies. Plasma input volumes for the
reference VL testing were 100 ml [17,24], 200 ml [23], 500 ml [14],
600 ml [21], 1000 ml [25] or unspecified [11,15,16,18–20,22]. One
study found the mean difference between DBS and plasma VL to
be 1.9460.06 log10 c/mL and provided this as a correction factor
Table 2. Sensitivity and Specificity of DBS for HIV early infant diagnosis compared to plasma.
Author Assay Sample size Sensitivity (%)* Specificity (%)*
Anitha et al. [26] Amplicor 1.5 64 100 100
Leelawiwat et al. [18] NucliSens v` 162 100 100
Nsojo et al. [27] Amplicor 1.5 325 100 99.6
Sherman et al. [28] Amplicor 1.5 2880 100 99.6
Stevens et al. [29] Amplicor 1.5 800 100 99
Stevens et al. [29] COBAS Ampliprep/Taqman 800 100 100
*sensitivity and specificity given against whole blood or plasma.
`version number unknown.
doi:10.1371/journal.pone.0086461.t002
Figure 2. Bias* per HIV viral load range, given for each assay. a haematocrit corrected. b viral load adjusted for smaller input volume. c
standard haematocrit value used to correct. * data obtained from Bland-Altman figures. *Bias (DBS-plasma) was plotted as the mean with 1 standard
deviation (SD). A negative value represents an HIV VL underestimation compared to plasma while a positive HIV VL bias represents an overestimation
of the HIV VL compared to plasma. SD was recalculated to 1 SD when presented as 1.96 or 2SD. In case of bias discrepancy between the text and
Bland Altman figure, the bias noted in the text was used (15).
doi:10.1371/journal.pone.0086461.g002
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for DBS VL calculations [20]. An Abbott RealTime HIV-1 assay
protocol for DBS samples is now available, incorporating this
correction factor. Haematocrit values can be used in the VL to
adjust for the volume of red blood cells, by estimating the amount
of plasma in a 50 ml whole blood sample. One study found that
haematocrit correction reduced the difference of DBS and plasma
VL from 20.43 log10 to 20.127 log10 [18]. An alternative is to
reduce the reference sample volume for a better VL correlation
between DBS and plasma [17]. Four out of 13 studies reported
that DBS VL were corrected for haematocrit or that DBS were
corrected for the smaller sample input volume [14,18,20,23].
Bias
The mean difference, or bias, between DBS and plasma VL
measurements (DBS – plasma) ranged from 20.77 (underestima-
tion) to +0.65 log10/mL (over estimation) across all studies
(Figure 2) 11, 15. For the Abbott RealTime HIV-1 assay,
51.9% up to 100% of the DBS HIV VL results were within 0.5 log
difference of plasma samples [11,15,19–21,25]. The percentage of
samples within 0.5 log for the Roche COBAS Taqman HIV-1 VL
and Versant HIV-1 kPCR were 78.4% [14] and 82.7% [22],
respectively. The Biomerieux NucliSens easyQ v1.1 was evaluated
by two studies in which 67% [11] and 94% [17] of the results were
within 0.5 log. The greatest variance between DBS and plasma
Figure 3. Sensitivity per viral load range of DBS compared to matching plasma samples.
doi:10.1371/journal.pone.0086461.g003
Figure 4. Number of publications matching a selection (18 out of 24) of quality criteria drawn from the STARD guidelines.
doi:10.1371/journal.pone.0086461.g004
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was found in studies using the Abbott RealTime HIV-1 assay
(Figure 2).
Detection limit and sensitivity
The lower detection limit (95% detection rate) of DBS samples
with the Abbott RealTime HIV-1 assay was determined by two
different studies to be 550 and 800 c/mL [15,19]. Andreotti et al.
found a low sensitivity when plasma VL samples were below
1,000 c/mL with the Roche COBAS Taqman HIV-1 VL assay
(20% detection rate) [14]. Evaluating DBS with the Versant HIV-
1 kPCR assay showed that 10 out of 98 samples were not detected
when with the corresponding plasma VL was below 597 c/mL
[22], which is relatively similar to the lower detection limit found
with the Abbott Realtime assay [15,19].
The current clinical threshold proposed by WHO to indicate
treatment failure is 5000 c/mL [30]. Depending on the technol-
ogy and the range of VL in the study population, the sensitivity of
DBS VL was found to be 78–100% compared to plasma at VL
levels below 1000 copies/ml [23] and varied from 85.1% to 100%
in two studies at 5000 c/mL [19,22]. The specificity of DBS at VL
levels of 5000 c/mL was determined in two studies and ranged
from 96.1% to 97% [19,22]. The sensitivities of DBS for samples
with a range of plasma VLs are shown in Table 1 and Figure 3.
Quality assessment
All 17 studies described sample storage conditions, discussed the
clinical relevance and were easily identified as evaluation studies,
with 8 of these describing the population sampled. Furthermore,
only eight studies described the distribution or range of HIV VL of
the sampled population. Overall, the quality of the papers scored
an average of 51% (SD=9%, range: 25%–63%), based on the
STARD guidelines (Figure 4).
Discussion
DBS samples have been used for many years for the diagnosis of
infectious diseases [31–33], including the diagnosis of HIV. DBS
have been shown to be an extremely useful tool in increasing the
access to diagnostic tests, particularly in remote regions. In
addition to the practical benefits of using DBS samples, the costs of
sample collection and shipment are low compared to plasma
samples [34]. Whilst DBS samples appear to be useful for EID and
HIV VL measurements, concerns exist with respect to the assays
and protocols.
Although literature reviews have been previously published
regarding the feasibility of using DBS for HIV VL [4,35,36], no
literature review has been published that has reviewed HIV EID
using DBS samples. The results shown in this study are
comparable with other reviews previously published [35,36].
The review published in 2009 [36] included in-house HIV VL
assays, while in this study we focused on commercially available
assays and assessed the quality of the papers. Additionally, the
previous review included studies evaluating dried serum or plasma
spots. Although these alternatives have some advantages over
DBS: HIV VL estimations are easier since HIV DNA is not
present in plasma but they still require phlebotomy. Serum and
plasma spots are more challenging to collect compared to DBS
and basic laboratory equipment is required for the separation of
blood thus diminishing the value of filter paper.
The majority of studies identified by this review [11,14–24]
show that DBS can be used to monitor treatment failure at the
current WHO proposed threshold of 5000 c/ml. All assays
included in this review are sensitive enough to be used for DBS
samples with VL of 3,000 c/mL or greater.
The most important differences in study methods are input
volume and the extraction method, both of which contribute to
differences in mean bias and variability. Additionally, the method
of punching out the filter paper spot, the punch size, elution buffer
used, and the sample volume after extraction may alter HIV VL
results. Haematocrit correction, quantity of blood and quantity of
plasma processed, method of VL calculation, and cell associated
HIV RNA and DNA can alter VL measurements. When these
critical steps in processing DBS are addressed and resolved, only
then will it become possible to reduce result variances and develop
uniform protocols to compare sample collection methodologies.
The lower limit of detection in HIV VL quantitation assays
when using DBS is 550–1000 c/mL, whereas for plasma it can be
as low as 20 c/ml. Even so, the results indicate that DBS VL
results are less consistent and vary among the VL platforms. One
of the reasons DBS is not, and may never be, as sensitive as plasma
in detecting low levels of HIV VL is because of the differences in
sample volume between DBS (20–25 ml) and plasma 100 ml to
1.0 mL). When an HIV VL platform has no specific DBS protocol
it is necessary to adjust the VL reading for the smaller volume of a
DBS sample to obtain a final result comparable to a plasma
sample. Unfortunately, most studies did not indicate how they
corrected DBS VL results, limiting the ability to further assess this
in greater detail.
The DBS VL can be recalculated to plasma VL c/mL by
applying the difference between plasma and DBS sample volume.
To make the calculation, haematocrit values can be obtained to
adjust DBS VL results by calculating the amount of plasma in a
DBS sample [18]. Two studies using haematocrit corrections
showed that results based on the assumption that 50% of the
population is anemic are comparable to corrections based on
individual haematocrit values [18,37]. These calculations are
important to compare DBS VL results between authors and to
understand the effects of these adjustments on over- or under-
quantification of HIV VL results. It is recommended that
manufacturers publish DBS protocols to help standardise meth-
odology.
Unlike a plasma VL test which measures only cell free HIV
RNA, a DBS VL also measures proviral DNA as well as cell-
associated RNA, potentially leading to an overestimation of VL
when using DBS [21]. Monleau et al treated DBS samples with
DNase and found that DNA contributes largely to the HIV VL
measurements in DBS samples [38]. The contribution of DNA in
HIV VL measurements in DBS has also been noted in samples
that are undetectable by plasma VL [22]. The Biomerieux
NucliSens EasyQ platform is based on isothermal RNA amplifi-
cation so HIV DNA is not detected. It can be expected that the
levels of proviral DNA and intracellular virions in a sample will
differ between patients, and within a single patient due to
biological variation. This would imply that a standard correction
would be inaccurate and a more detailed procedure would be
necessary. Lofgren et al [24] showed that when using a cut-off of
400 c/mL, the specificity of DBS is low (87%), as seven samples
were over-quantified. As DBS adds more variability to VL results
(20.77 to 0.65 log10/mL), it is essential to critically review the
laboratory procedures for DBS and minimize variability of each
sample process step. Because of the difference in sample volume
and the presence of HIV DNA as well as cellular HIV RNA in
DBS samples, the quantitation of HIV is complex. In our opinion,
a carefully designed and executed reference curve for DBS
samples needs to be made for each assay and population.
In contrast to HIV RNA assays, the presence of proviral HIV
DNA or cell associated HIV RNA increases the sensitivity of EID
assays. DBS samples are regularly used for early infant diagnosis
Systematic Review of DBS for HIV Viral Load
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and generally accepted as a sensitive method when venous blood
cannot be collected [1,39–41]. Although all studies reviewed here
showed good sensitivity, the specificity was slightly less than with
fresh blood samples (99–100%). HIV VL in infants is high with
inter-quartile ranges of 0.5 million to almost 5 million copies/ml at
6 weeks of age [42] in the absence of prophylactic antiretroviral
drugs, suggesting that DBS are a suitable sample [43]. However, as
more mothers and infants receive antiretroviral drugs to prevent
mother-to-child transmission of HIV, lower HIV RNA levels in
infected babies will be observed. Although more evaluations are
needed, the use of HIV VL assays for EID with DBS samples
could potentially decrease costs, improve access to EID and
simplify testing procedures [44,45].
Conclusion
There is an urgent need to improve access to VL and EID in
resource-limited settings, particularly at peripheral sites where,
increasingly, HIV clinical management is being provided. This is
consistent with the need to decentralize treatment and care to
improve access and retention in care [46]. To date, however,
access has been limited by technologies that require sampling at
central laboratories.
DBS can be used as an alternative to plasma for HIV VL
quantitation based on the suggested threshold of 5,000 c/mL, but
challenges surrounding the pre-extraction and analytical stages
need to be resolved. Adequate sensitivities can be obtained from
1000 c/mL onwards, and 100% sensitivity is obtained across all
platforms when HIV VL is over 3,000 c/mL.
Assays for HIV VL and EID detect nucleic acids and are
performed on similar laboratory equipment and HIV VL assays
have been evaluated for use for early infant diagnosis. Using the
same platform and consumables for two diagnostic tests allows for
economies that are particularly advantageous for resource-limited
settings. If HIV VL and EID testing were performed on a single
technology platform, a standardized approach for sampling,
storing, and processing DBS samples would be essential to allow
successful implementation.
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